Study: Femara bests tamoxifen in avoiding breast cancer return

12/28/2005 | Guardian (London), The

A large study of the Novartis drug letrozole, marketed as Femara, shows it is more useful than tamoxifen for treating women at risk of having breast cancer return. The two drugs were compared in a study of 8,000 women, and those women whose breast cancer had spread to their lymph nodes experienced 29% fewer cases of their cancer returning when treated with letrozole.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ